Checklist Tool in Engaging Patients in the Discharge Planning Process

Malignant Neoplasm Clinical Trial

— TEPID  

Official title:

Tool to Engage Patients in Discharge (TEPID)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02942524
• Other study ID #: OSU-14237
• Secondary ID: NCI-2016-01308
• Status: Completed
• Phase: N/A
• Start date: April 2016
• Est. completion date: August 4, 2017

Study information

• Verified date: July 2020
• Source: Ohio State University Comprehensive Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial studies how well a checklist tool works in engaging patients in the discharge planning process. Engaging patients in the discharge process may increase participation in the discharge process and improve discharge outcomes, understanding of care after hospitalization, and decrease complications.

Description:

PRIMARY OBJECTIVES:

I. Measure the impact on discharge and transition satisfaction of utilizing questions from the Consumer Assessment of Healthcare Providers and Systems (CHAPS) patient satisfaction survey.

II. Measure the impact of the Tool to Engage Patients in Discharge (TEPID) on patient's Readiness for Hospital Discharge and Problems After Discharge Questionnaire-English (PADQ-E) results.

III. Measure the impact on decreasing healthcare utilization measures: readmission rates within 30 days from hospital discharge, hospital length of stay of admission in hospital, and emergency department visits within 30 days of hospital discharge.

OUTLINE:

Patients complete the TEPID checklist of items during hospital stay.

After completion of the study, patients are followed up for 35 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 450
• Est. completion date: August 4, 2017
• Est. primary completion date: August 4, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 19 Years and older

Eligibility

Inclusion Criteria:

• Patients fluent in English, conscious, coherent, and alert or have an adult caregiver present that is fluent in English will be identified for the TEPID research project

Exclusion Criteria:

• Patients discharged to another inpatient facility (hospice, skilled nursing facility, long term acute care hospital [LTACH], or acute rehab) or patients discharged home with hospice will be excluded

• Any patients that are transferred to another unit prior to discharge will be excluded

Related Conditions & MeSH terms

• Hospitalization
• Malignant Neoplasm
• Neoplasms
• Transitional Care Planning

Intervention

Other:
• Communication Intervention
Complete TEPID
• Questionnaire Administration
Ancillary studies
• Survey Administration
Ancillary studies

Locations

Country	Name	City	State
United States	Ohio State University Comprehensive Cancer Center	Columbus	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Ohio State University Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average score from the PADQ-E	A simple analysis of variance (ANOVA) model with floor as a fixed blocking factor treatment (TEPID or no TEPID) as a fixed factor. Unit appears in the model as a nested factor within treatment, and statistical tests will be adjusted for this nesting structure. The main test of interest in each model is the overall effect of treatment, which quantifies the effect of TEPID on the average score for the response. P-values below 0.05 for this effect will be considered statistically significant.	Up to 12 months
Primary	Average score from the Readiness for Hospital Discharge Scale	A simple ANOVA model with floor as a fixed blocking factor treatment (TEPID or no TEPID) as a fixed factor. Unit appears in the model as a nested factor within treatment, and statistical tests will be adjusted for this nesting structure. The main test of interest in each model is the overall effect of treatment, which quantifies the effect of TEPID on the average score for the response. P-values below 0.05 for this effect will be considered statistically significant.	Up to 12 months
Primary	Emergency department visits	A generalized linear model will be used for the binary responses (readmission and ED visit).	Up to 12 months
Primary	Patient satisfaction as measured by the Press Ganey Consumer Assessment of Healthcare Providers and Systems Survey	A simple ANOVA model with floor as a fixed blocking factor treatment (TEPID or no TEPID) as a fixed factor. Unit appears in the model as a nested factor within treatment, and statistical tests will be adjusted for this nesting structure. The main test of interest in each model is the overall effect of treatment, which quantifies the effect of TEPID on the average score for the response. P-values below 0.05 for this effect will be considered statistically significant.	Up to 12 months
Primary	Readmission rates	A generalized linear model will be used for the binary responses (readmission and ED visit).	Up to 12 months

External Links

•   jamesline